The Cunningham Panel™ – Autoantibody testing for neuropsychiatric symptoms

Leading clinicians from all over the world are utilizing the Cunningham Panel™ to assist in their diagnosis and treatment of individuals with infection-triggered autoimmune basal ganglia encephalitis, including *PANS/PANDAS.

This autoimmune encephalopathy (AE)/basal ganglia encephalitis (BGE) panel, called the Cunningham Panel™ is unique and based on over two decades of research. These high complexity tests are comprised of five assays and is offered exclusively through Moleculera Labs, Inc.

* PANS – Pediatric Acute-onset Neuropsychiatric Syndrome; PANDAS – Pediatric Autoimmune Neuropsychiatric Disorder associated with Streptococcal infections.

Cunningham Panel Dr. Eboni Cornish Testimonial

Dr. Eboni Cornish (Part 1)

Integrative/Functional Medicine, Amen Clinics

This is the only test that could help me determine whether the root cause was of an infectious etiology or inflammatory.

Cunningham Panel Dr. Eboni Cornish Testimonial

Dr. Eboni Cornish (Part 2)

Integrative/Functional Medicine, Amen Clinics

Patient Case: Once homebound with severe neuropsychiatric symptoms, this young girl is now back in school. Test results changed my treatment plan to focus on agents sensitive to crossing the blood-brain barrier.

Cunningham Panel Dr. Kaplan’s Testimonial

Dr. Gary Kaplan (Part 1)

Kaplan Center for Integrative Medicine

The Cunningham Panel™ becomes crucial in my workup of these patients to find out how much of an autoimmune process I’ve got going on.

Cunningham Panel Dr. Kapalan’s Patient Case

Dr. Gary Kaplan (Part 2)

Kaplan Center for Integrative Medicine

Patient Case: A 17-year-old with rage attacks, extreme weight loss and OCD

Cunningham Panel Dr. Latimer’s Testimonial

Dr. Beth Latimer

Pediatric Neurologist

I think that the CaMKinase is the most important assay and changes with the severity of disease, at least in my experience.

Cunningham Panel Dr. Magdalena A. Cubala-Kucharska’s Testimonial

Dr. Magdalena A. Cubala-Kucharska

Director of Arcana Institute of Integrative Medicine
Warsaw, Poland

The Cunningham Panel helps you determine whether a patient still needs prolonged treatment or maybe it’s time to stop.

Cunningham Panel Dr. deAntonio’s Testimonial

Dr. Michele deAntonio


The Panel can help family members understand that this is a physiological condition.

Cunningham Panel Dr. Greenberg’s Patient Case

Dr. Rosalie Greenberg

Pediatric and Adolescent Psychiatrist

I’m able to use the Panel to show to the parents – that these are abnormalities. That means your child’s brain is being attacked, basically.

B. Robert Mozayeni, MD

Medical and Clinical Advisor

B. Robert Mozayeni MD

Dr. B. Robert Mozayeni was trained in Internal Medicine and Rheumatology at Yale and at NIH. He has had pre- and post-doctoral Fellowships in Molecular Biophysics and Biochemistry at Yale, and also at NIH where he was a Howard Hughes Research Scholar at LMB/DCBD/NCI and later, Senior Staff Fellow at LMMB/NHLBI/NIH. Editorial board of Infectious Diseases – Surveillance, Prevention and Treatment. Past President of the International Lyme and Associated Diseases Society (ILADS).

He is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation and is a co-founder of the Foundation for the Study of Inflammatory Diseases. He is a Founder of the Foundation for the Study of Inflammatory Diseases to crowd-source medical solutions for complex conditions using existing knowledge, diagnostic methods, and therapies to meet patient needs immediately. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a Board member of the Human-Kind Alliance. Dr. Mozayeni has held admitting privileges (since 1994) on the clinical staff of Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.

Safedin Sajo Beqaj, PhD, HCLD, CC (ABB)

Moleculera Labs, Clinical Laboratory Advisor
Medical Database, Inc., President and CEO

Sajo Baqaj, PhD

Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.

Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.

Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Children’s Hospital and Northwestern University from 2003-2005.

Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche (Vantana) CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.

He is a member of several medical and scientific associations including the Association of Molecular Pathology, American Association of Clinical Chemistry and the Pan Am Society for Clinical Virology. He has served on a number of clinical laboratory regulatory and scientific committees, and has assisted several laboratories and physicians as a Clinical Laboratory Consultant.